Paclitaxel delivery from PLGA foams for controlled release in post-surgical chemotherapy against glioblastoma multiforme

Biomaterials

Volumn 30, Issue 18, 2009, Pages 3189-3196

  Ong, Benjamin Y S ^a   Ranganath, Sudhir H ^a   Lee, Lai Yeng ^a   Lu, Fan ^a   Lee, How Sung ^a   Sahinidis, Nikolaos V ^b   Wang, Chi Hwa ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b CARNEGIE MELLON UNIVERSITY   (United States)

Author keywords

Foams; Glioma; In vivo bio distribution; Paclitaxel; PLGA; Sustained release

Indexed keywords

GLIOMA; IN VIVO BIO-DISTRIBUTION; PACLITAXEL; PLGA; SUSTAINED RELEASE;

CELL DEATH; CHEMOTHERAPY; DRUG PRODUCTS; MICROPOROSITY; QUENCHING;

IMPLANTS (SURGICAL);

PACLITAXEL; POLYGLACTIN;

ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELL STRAIN C6; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXPOSURE; DRUG SCREENING; FOAM; GLIOBLASTOMA; GLIOMA CELL; IN VITRO STUDY; IN VIVO STUDY; KINETICS; MALE; MOUSE; NONHUMAN; POSTOPERATIVE CARE; PRIORITY JOURNAL; RAT; TREATMENT DURATION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BRAIN NEOPLASMS; CELL DIVISION; CELL LINE, TUMOR; CHEMOTHERAPY, ADJUVANT; DELAYED-ACTION PREPARATIONS; DRUG EVALUATION, PRECLINICAL; DRUG IMPLANTS; GLIOBLASTOMA; LACTIC ACID; MICE; MICE, INBRED BALB C; PACLITAXEL; POLYGLYCOLIC ACID; POROSITY; RATS; RATS, WISTAR; TISSUE DISTRIBUTION;

RATTUS;

EID: 64649095837     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2009.02.030     Document Type: Article

References (27)

1. Lesniak M.S., Upadhyay U., Goodwin R., Tyler B., and Brem H. Local delivery of doxorubicin for the treatment of malignant brain tumors in rats. Anticancer Res 28 6B (2005) 3825-3831
2. Kemper E.M., van Zandbergen A.E., Cleypool C., Mos H.A., Boogerd W., Beijnen J.H., et al. Increased penetration of paclitaxel into the brain by inhibition of P-Glycoprotein. Clin Cancer Res 9 7 (2003) 2849-2855
3. Westphal M., Hilt D.C., Bortey E., Delavault P., Olivares R., Warnke P.C., et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol 5 (2003) 79-88
4. Weber E.L., and Goebel E.A. Cerebral edema associated with Gliadel wafers: two case studies. Neuro Oncol 7 1 (2005) 84-89
5. Brem H., and Gabikian P. Biodegradable polymer implants to treat brain tumors. J Control Release 74 1-3 (2001) 63-67
6. Li J., Strobel G., Sidhu R., Hess W.M., and Ford E.J. Endophytic taxol-producing fungi from bald cypress, Taxodium distichum. Microbiology 142 (1996) 2223-2226
7. Fang G.F., Chang B.S., Kim C.N., Perkins C., Thompson C.B., and Bhalla K.N. "Loop" domain is necessary for taxol-induced mobility shift and phosphorylation of Bcl-2 as well as for inhibiting taxol-induced cytosolic accumulation of cytochrome c and apoptosis. Cancer Res 58 (1998) 3202-3208
8. Rodi D.J., Janes R.W., Sanganee H.J., Holton R.A., Wallace B.A., and Makowski L. Screening of a library of phage-displayed peptides identifies human Bcl-2 as a taxol-binding protein. J Mol Biol 285 (1999) 197-203
9. Hempel G., Rube C., Mosler C., Wienstroer M., Wagner-Bohn A., Schuck A., et al. Population pharmacokinetics of low-dose paclitaxel in patients with brain tumors. Anticancer Drugs 14 6 (2003) 417-422
10. Rowinsky E.K., Burke P.J., Karp J.E., Tucker R.W., Ettinger G.S., and Donehower R.C. Phase I and pharmacodynamic study of taxol in refractory acute leukemias. Cancer Res 49 (1989) 4640-4647
11. Klecker R.W., Jamis-Dow C.A., Egorin M.J., Erkman K., Parker R.J., Stevens R., et al. Distribution and metabolism of 3H-taxol in the rat. Proc Am Assoc Cancer Res 34 (1993) 381
12. Fellner S., Bauer B., Miller D.S., Schaffrik M., Fankhanel M., Spruss T., et al. Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. J Clin Invest 110 9 (2002) 1309-1318
13. Tseng S.H., Bobola M.S., Berger M.S., and Silber J.R. Characterization of paclitaxel (Taxol) sensitivity in human glioma- and medulloblastoma-derived cell lines. Neuro Oncol 1 2 (1999) 101-108
14. Walter K.A., Cahan M.A., Gur A., Tyler B., Hilton J., Colvin O.M., et al. Interstitial taxol delivered from a biodegradable polymer implant against experimental malignant glioma. Cancer Res 54 (1994) 2207-2212
15. Wang J., Ng C.W., Win K.Y., Shoemakers P., Lee T.K.Y., Feng S.S., et al. Release of paclitaxel from polylactide-co-glycolide (PLGA) microparticles and discs under irradiation. J Microencapsul 20 3 (2003) 317-327
16. Li K.W., Dang W., Tyler B.M., Troiano G., Tihan T., Brem H., et al. Polilactofate microspheres for paclitaxel delivery to central nervous system malignancies. Clin Cancer Res 9 (2003) 3441-3447
17. Von Eckardstein K.L., Reszka R., and Kiwit J.C.W. Intracavitary chemotherapy (paclitaxel/carboplatin liquid crystalline cubic phases) for recurrent glioblastoma - clinical observations. J Neurooncol 74 3 (2005) 305-309
18. von Eckardstein K.L., Patt S., Kratzel C., Kiwit J.C.W., and Reszka R. Local chemotherapy of F98 rat glioblastoma with paclitaxel and carboplatin embedded in liquid crystalline cubic phases. J Neurooncol 72 (2005) 209-215
19. Cahan M.A., Walter K.A., Colvin O.M., and Brem H. Cytotoxicity of taxol in vitro against human and rat malignant brain tumors. Cancer Chemother Pharmacol 33 (1994) 441-444
20. Naraharisetti P.K., Ong B.Y.S., Xie J.W., Lee T.K.Y., Wang C.H., and Sahinidis N.V. In vivo performance of implantable biodegradable preparations delivering paclitaxel and etanidazole for the treatment of glioma. Biomaterials 28 5 (2007) 886-894
21. Ranganath S.H., and Wang C.H. Biodegradable microfiber implants delivering paclitaxel for post-surgical chemotherapy against malignant glioma. Biomaterials 29 (2008) 2996-3003
22. 2 gas-foaming method as a scaffold for three-dimensional growth of HEP3B cells. Biotechnol Bioeng 100 5 (2008) 998-1009
23. Benda P., Lightbody J., Sato G., Levine L., and Sweet W. Differentiated rat glial cell strain in tissue culture. Science 26 (1968) 370-371
24. Siepmann J., Siepmann F., and Florence A.T. Local controlled drug delivery to the brain: mathematical modeling of the underlying mass transport mechanisms. Int J Pharm 314 (2006) 101-119
25. Fung L.K., Ewend M.G., Sills A., Sipos E.P., Thomspon R., Watts M., et al. Pharmacokinetics of interstitial delivery of carmustine, 4-hydroxycyclophosphamide, and paclitaxel from a biodegradable polymer implant in the monkey brain. Cancer Res 58 (1998) 672-684
26. Sonnichsen D.S., and Relling M.V. Clinical pharmacokinetics of paclitaxel. Clin Pharmacokinet 27 4 (1994) 256-269
27. ® healthcare series. Thomson Healthcare: Accessed Online Dec 2008. Available from URL: http://www.thomsonhc.com.libproxy1.nus.edu.sg/hcs/librarian/ND_T/HCS/ND_PR/Main/CS/FC7307/DUPLICATIONSHIELDSYNC/746722/ND_PG/PRIH/ND_B/HCS/SBK/6/ND_P/Main/PFPUI/cw129y22KeGpQT/PFActionId/hcs.common.RetrieveDocumentCommon/DocId/1377/ContentSetId/31/SearchTerm/paclitaxel%20/SearchOption/ExactMatch.